Chugai Pharmaceutical Co. Ltd
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL… Read more
Market Cap & Net Worth: Chugai Pharmaceutical Co. Ltd (CHGCF)
Chugai Pharmaceutical Co. Ltd (PINK:CHGCF) has a market capitalization of $72.79 Billion ($72.79 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #717 globally and #565 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chugai Pharmaceutical Co. Ltd's stock price $44.23 by its total outstanding shares 1645713419 (1.65 Billion).
Chugai Pharmaceutical Co. Ltd Market Cap History: 2015 to 2025
Chugai Pharmaceutical Co. Ltd's market capitalization history from 2015 to 2025. Data shows growth from $8.84 Billion to $72.79 Billion (0.00% CAGR).
Chugai Pharmaceutical Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chugai Pharmaceutical Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.06x
Chugai Pharmaceutical Co. Ltd's market cap is 0.06 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.17x
Chugai Pharmaceutical Co. Ltd's market cap is 0.17 times its annual earnings
11.15x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $7.40 Billion | $491.78 Billion | $53.59 Billion | 0.02x | 0.14x |
| 2017 | $11.24 Billion | $534.20 Billion | $72.71 Billion | 0.02x | 0.15x |
| 2018 | $16.31 Billion | $579.79 Billion | $92.49 Billion | 0.03x | 0.18x |
| 2019 | $17.56 Billion | $686.18 Billion | $157.56 Billion | 0.03x | 0.11x |
| 2020 | $70.08 Billion | $786.95 Billion | $214.73 Billion | 0.09x | 0.33x |
| 2021 | $49.60 Billion | $999.76 Billion | $303.00 Billion | 0.05x | 0.16x |
| 2022 | $40.04 Billion | $1.26 Trillion | $374.43 Billion | 0.03x | 0.11x |
| 2023 | $59.86 Billion | $1.11 Trillion | $325.47 Billion | 0.05x | 0.18x |
| 2024 | $76.26 Billion | $1.17 Trillion | $387.32 Billion | 0.07x | 0.20x |
| 2025 | $72.79 Billion | $1.26 Trillion | $434.39 Billion | 0.06x | 0.17x |
Competitor Companies of CHGCF by Market Capitalization
Companies near Chugai Pharmaceutical Co. Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Chugai Pharmaceutical Co. Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Chugai Pharmaceutical Co. Ltd Historical Marketcap From 2015 to 2025
Between 2015 and today, Chugai Pharmaceutical Co. Ltd's market cap moved from $8.84 Billion to $ 72.79 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $72.79 Billion | -4.55% |
| 2024 | $76.26 Billion | +27.39% |
| 2023 | $59.86 Billion | +49.49% |
| 2022 | $40.04 Billion | -19.26% |
| 2021 | $49.60 Billion | -29.23% |
| 2020 | $70.08 Billion | +299.18% |
| 2019 | $17.56 Billion | +7.65% |
| 2018 | $16.31 Billion | +45.13% |
| 2017 | $11.24 Billion | +51.88% |
| 2016 | $7.40 Billion | -16.31% |
| 2015 | $8.84 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Chugai Pharmaceutical Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $72.79 Billion USD |
| MoneyControl | $72.79 Billion USD |
| MarketWatch | $72.79 Billion USD |
| marketcap.company | $72.79 Billion USD |
| Reuters | $72.79 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.